Meeting
2023 ASCO Gastrointestinal Cancers Symposium
The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation.
Authors
Sun Young Jeong
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea;
Sun Young Jeong , Seung Tae Kim , Jae Yeon Jang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 598)
DOI
10.1200/JCO.2023.41.4_suppl.598
Abstract #
598
Poster Bd #
F10
Abstract Disclosures
Similar Posters
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.
First Author: Laurent Mhanna
Poster
2023 ASCO Annual Meeting
Phase II trial of XmAb20717 (vudalimab) in patients with advanced biliary tract cancers.
First Author: William Joseph Chapin
Poster
2019 ASCO Annual Meeting
Dynamic changes of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) during treatment with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC).
First Author: Alessandro Russo
First Author: Jennifer Aline Marks